Clinical trial

Study of Intravenous NRX-1074 in Patients With Major Depressive Disorder

NCT02067793

Drugs and interventions used in this trial

4 registered

These interventions are listed by ClinicalTrials.gov. An RxNorm link indicates a mapped medicine record; the registry name alone is not proof of a specific branded formulation.

Search this trial's interventions

DRUG · Unmapped registry intervention NRX-1074 1 mg Find medicine records · Find other trials using this name

DRUG · Unmapped registry intervention Placebo Find medicine records · Find other trials using this name

DRUG · Unmapped registry intervention NRX-1074 5 mg Find medicine records · Find other trials using this name

DRUG · Unmapped registry intervention NRX-1074 10 mg Find medicine records · Find other trials using this name

Study at a glance

Registry-backed

Study of Intravenous NRX-1074 in Patients With Major Depressive Disorder

Design: INTERVENTIONAL · Status: COMPLETED · Phase: PHASE2

Read study objectives, eligibility and outcome measures at ClinicalTrials.gov

StatusCOMPLETED

Study typeINTERVENTIONAL

Start date2014-03-01

PhasePHASE2

Conditions

Major Depressive Disorderverified · MONDO: major depressive disorder

Interventions

NRX-1074 1 mgDRUG

PlaceboDRUG

NRX-1074 5 mgDRUG

NRX-1074 10 mgDRUG

Sponsors & collaborators

Naurex, Inc, an affiliate of Allergan plclead sponsor

Mapped research locations

New YorkNew York, United States1 DallasTexas, United States1 Salt Lake CityUtah, United States1 MemphisTennessee, United States1 WichitaKansas, United States1 CharlottesvilleVirginia, United States1 OaklandCalifornia, United States1

Registry source

Open the source record to verify current eligibility, contacts, locations and registry updates.

Open NCT02067793 on ClinicalTrials.gov ↗

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.